Download PDF
Arthritis und Rheuma 2019; 39(06): 385-390
DOI: 10.1055/a-1037-0874
Schwerpunkt
© Georg Thieme Verlag KG Stuttgart · New York

Medikamenten-assoziierte Kiefernekrosen – Relevanz aus rheumatologischer Sicht?

Medication-related osteonecrosis of the jaw – any relevance from the rheumatological point of view?
Sebastian Hoefert
1   Klinik und Poliklinik für Mund-, Kiefer- und Gesichtschirurgie, Universitätsklinikum Tübingen, Tübingen
› Author Affiliations
Further Information

Publication History

Publication Date:
18 December 2019 (online)

Also available at
    Permissions and Reprints

ZUSAMMENFASSUNG

Die Medikamenten-assoziierte Kiefernekrose (MRONJ) ist eine schwere Nebenwirkung einer Antiresorptivatherapie mit Bisphosphonaten und Denosumab sowie von antiangiogenetischen Medikamenten. 16 Jahre nach der Erstbeschreibung der Medikamenten-assoziierten Kiefernekrose konnten noch nicht alle Ursachen geklärt und das Risiko für das Auftreten einer Nekrose minimiert werden. Neue Substanzen und Targeted Therapies können ebenfalls für Nekrosen des Kiefers mit ursächlich sein. Patienten mit rheumatischen Erkrankungen, die mit Biologika und DMARDs behandelt werden, stellen dabei eine besondere Risikogruppe dar und werden nach der neuen S3-Leitlinie „Antiresorptiva-assoziierte Kiefernekrosen (AR-ONJ)“ in ein „mittleres Risikoprofil“ eingeordnet. Aus diesem Grunde ergibt sich eine Relevanz dieses Krankheitsbildes für den rheumatologisch tätigen Mediziner. Dieses soll Anlass sein, über dieses Krankheitsbild zu berichten und für diese Problematik zu sensibilisieren.

ABSTRACT

The Medication-related Osteonecrosis of the Jaw (MRONJ) is a severe side effect of antiresorptive medication with bisphosphonates, denosumab and as antiangiogenic substances. 16 years after the first description of MRONJ is the etiology still unclear and prevention still difficult. New medications as New Substances and Targeted Therapies could cause necrosis of the jaw, too. Patients with rheumatic diseases and medications as biologicals and DMARDs are in special risk for necrosis. Regarding the new German Guideline “Antiresorptiva-assoziierte Kiefernekrosen (AR-ONJ)” they are classified as “Medium Risk Patients”. Awareness of MRONJ and to sensitize is the primary aim of this publication.

Schlüsselwörter

MRONJ - Kiefernekrose - Prophylaxe - Osteoporose - DMARDs

Keywords

MRONJ - osteonecrosis of the jaw - prophylaxis - DMARDs
 

  • Literatur

  • 1 Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117
    CrossrefPubMedGoogle Scholar
  • 2 Ruggiero SL, Dodson TB, Fantasia J. et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw-2014 Update. J Oral Maxillofac Surg 2014; 72: 1938-1956 doi:10.1016/j.joms.2014.04.031
    CrossrefPubMedGoogle Scholar
  • 3 Ruggiero SL, Dodson TB, Assael LA. et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009; 67: 2-2 doi:10.1016/j.joms.2009.01.009
    CrossrefPubMedGoogle Scholar
  • 4 Yoneda T, Hagino H, Sugimoto T. et al. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw. Journal of Bone and Mineral Metabolism 2016 doi:10.1007/s00774-016-0810-7. doi:10.1007/s00774-016-0810-7
    PubMedGoogle Scholar
  • 5 Grötz KP. S3-Leitlinie Bisphosphonat-assoziierte Kiefernekrosen. wwwawmforg/leitlinien/detail/ll/007-091html 2012 AWMF-Register Nr. 007/091
    PubMedGoogle Scholar
  • 6 Schiegnitz EA-N B, Hoefert S, Otto S. et al. S3-Leitlinie Antiresorptiva-assoziierte Kiefernekrosen (AR-ONJ). https://wwwawmforg/uploads/tx_szleitlinien/007-091l_S3_Antiresorptiva-assoziierte-Kiefernekrosen-AR-ONJ_2018-12pdf 2018
    PubMedGoogle Scholar
  • 7 Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws AAoO, Maxillofacial S American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 369-376 doi:10.1016/j.joms.2006.11.003
    CrossrefPubMedGoogle Scholar
  • 8 Svejda B, Muschitz C, Gruber R. et al. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)]. Wien Med Wochenschr 2016; 166: 68-74 doi:10.1007/s10354-016-0437-2
    CrossrefPubMedGoogle Scholar
  • 9 Javelot MJ, Sergheraert J, Agbo-Godeau S. et al. Rituximab as a trigger factor of medication-related osteonecrosis of the jaw. A case report. J Stomatol Oral Maxillofac Surg 2019 doi:10.1016/j.jormas.2019.06.009. doi:10.1016/j.jormas.2019.06.009
    PubMedGoogle Scholar
  • 10 Son HJ, Kim JW, Kim SJ. Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw. Maxillofac Plast Reconstr Surg 2019; 41: 26 doi:10.1186/s40902-019-0210-8
    CrossrefPubMedGoogle Scholar
  • 11 Yarom N, Shapiro CL, Peterson DE. et al. Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline. J Clin Oncol 2019; 37: 2270-2290 doi:10.1200/JCO.19.01186
    CrossrefPubMedGoogle Scholar
  • 12 Aghaloo T, Hazboun R, Tetradis S. Pathophysiology of Osteonecrosis of the Jaws. Oral Maxillofac Surg Clin North Am 2015; 27: 489-496 doi:10.1016/j.coms.2015.06.001
    CrossrefPubMedGoogle Scholar
  • 13 Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med 2013; 11: 88 doi:10.1186/1741-7015-11-88
    CrossrefPubMedGoogle Scholar
  • 14 Radfar L, Ahmadabadi RE, Masood F. et al. Biological therapy and dentistry: a review paper. Oral Surg Oral Med Oral Pathol Oral Radiol 2015; 120: 594-601 doi:10.1016/j.oooo.2015.07.032
    CrossrefPubMedGoogle Scholar
  • 15 Hayashi M, Morimoto Y, Iida T. et al. Risk of Delayed Healing of Tooth Extraction Wounds and Osteonecrosis of the Jaw among Patients Treated with Potential Immunosuppressive Drugs: A Retrospective Cohort Study. Tohoku J Exp Med 2018; 246: 257-264 doi:10.1620/tjem.246.257
    CrossrefPubMedGoogle Scholar
  • 16 Pountos I, Giannoudis PV. Effect of methotrexate on bone and wound healing. Expert Opin Drug Saf 2017; 16: 535-545 doi:10.1080/14740338.2017.1310839
    CrossrefPubMedGoogle Scholar
  • 17 Schwaneck EC, Streit A, Krone M. et al. Osteoporosis therapy in patients with inflammatory rheumatic diseases and osteonecrosis of the jaw. Z Rheumatol 2019 doi:10.1007/s00393-019-0606-y. doi:10.1007/s00393-019-0606-y
    PubMedGoogle Scholar
  • 18 Rogers SN, Palmer NO, Lowe D. et al. United Kingdom nationwide study of avascular necrosis of the jaws including bisphosphonate-related necrosis. Br J Oral Maxillofac Surg 2015; 53: 176-182 doi:10.1016/j.bjoms.2014.11.008
    CrossrefPubMedGoogle Scholar
  • 19 Anagnostis P, Paschou SA, Mintziori G. et al. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas 2017; 101: 23-30 doi:10.1016/j.maturitas.2017.04.008
    CrossrefPubMedGoogle Scholar
  • 20 Hayashida S, Yanamoto S, Fujita S. et al. Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw. J Bone Miner Metab 2019 doi:10.1007/s00774-019-01035-7. doi:10.1007/s00774-019-01035-7
    PubMedGoogle Scholar
  • 21 Goodman SM. Rheumatoid arthritis: Perioperative management of biologics and DMARDs. Semin Arthritis Rheum 2015; 44: 627-632 doi:10.1016/j.semarthrit.2015.01.008
    CrossrefPubMedGoogle Scholar
  • 22 Clay M, Mazouyes A, Gilson M. et al. Risk of postoperative infections and the discontinuation of TNF inhibitors in patients with rheumatoid arthritis: A meta-analysis. Joint Bone Spine 2016; 83: 701-705 doi:10.1016/j.jbspin.2015.10.019
    CrossrefPubMedGoogle Scholar
  • 23 Godot S, Gottenberg JE, Paternotte S. et al. Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry. Arthritis Care Res (Hoboken) 2013; 65: 1874-1879 doi:10.1002/acr.22056
    Google Scholar
  • 24 Latourte A, Gottenberg JE, Luxembourger C. et al. Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry. Rheumatology (Oxford) 2017; 56: 629-637 doi:10.1093/rheumatology/kew476
    PubMedGoogle Scholar
  • 25 Mabille C, Degboe Y, Constantin A. et al. Infectious risk associated to orthopaedic surgery for rheumatoid arthritis patients treated by anti-TNFalpha. Joint Bone Spine 2017; 84: 441-445 doi:10.1016/j.jbspin.2016.06.011
    CrossrefPubMedGoogle Scholar
  • 26 Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. N Engl J Med 2005; 353: 1711-1723 doi:10.1056/NEJMra050541
    CrossrefPubMedGoogle Scholar
  • 27 Kruger K, Albrecht K, Rehart S. et al. [Recommendations of the German Society for Rheumatology on the perioperative approach under therapy with DMARDs and biologicals in inflammatory rheumatic diseases]. Z Rheumatol 2014; 73: 77-84 doi:10.1007/s00393-013-1301-z
    CrossrefPubMedGoogle Scholar
  • 28 Hinson AM, Smith CW, Siegel ER. et al. Is bisphosphonate-related osteonecrosis of the jaw an infection? A histological and microbiological ten-year summary. Int J Dent 2014; 2014: 452737 doi:10.1155/2014/452737
    PubMedGoogle Scholar
  • 29 Stopeck AT, Fizazi K, Body JJ. et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 2016; 24: 447-455 doi:10.1007/s00520-015-2904-5
    CrossrefPubMedGoogle Scholar